Trista Haupt Wright et Chad Harris, « Twenty-One Cases Involving Alpha-Pyrrolidinovalerophenone (α-PVP) », Journal of Analytical Toxicology, vol. 40, no 5, , p. 396–402 (ISSN1945-2403, PMID27185821, DOI10.1093/jat/bkw029, lire en ligne, consulté le )
Christoph Sauer, Frank T. Peters, Claudia Haas et Markus R. Meyer, « New designer drug alpha-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques », Journal of Mass Spectrometry: JMS, vol. 44, no 6, , p. 952–964 (ISSN1096-9888, PMID19241365, DOI10.1002/jms.1571, lire en ligne, consulté le )
Douglas A. Smith, S. Stevens Negus, Justin L. Poklis et Bruce E. Blough, « Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys », Addiction Biology, vol. 22, no 5, , p. 1169–1178 (ISSN1369-1600, PMID27060605, DOI10.1111/adb.12399, lire en ligne, consulté le )
(en) Meltzer PC, Butler D, Deschamps JR et Madras BK, « 1-(4-Methylphenyl)-2-pyrrolidin-1-ylpentan-1-one (pyrovalerone ) analogs: a promising class of monoamine uptake inhibitors », J. Med. Chem., (PMID16480278, DOI10.1021/jm050797a, lire en ligne)
Kyoko Hataoka, Asuka Kaizaki-Mitsumoto et Satoshi Numazawa, « Alpha-PVP induces the rewarding effect via activating dopaminergic neuron », The Journal of Toxicological Sciences, vol. 42, no 5, , p. 539–543 (ISSN1880-3989, PMID28904288, DOI10.2131/jts.42.539, lire en ligne, consulté le )
Julie A. Marusich, Kateland R. Antonazzo, Jenny L. Wiley et Bruce E. Blough, « Pharmacology of novel synthetic stimulants structurally related to the bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV) », Neuropharmacology, vol. 87, , p. 206–213 (ISSN1873-7064, PMID24594476, PMCIDPMC4152390, DOI10.1016/j.neuropharm.2014.02.016, lire en ligne, consulté le )
Rimako Umebachi, Hiromichi Aoki, Mariko Sugita et Takayuki Taira, « Clinical characteristics of α-pyrrolidinovalerophenone (α-PVP) poisoning », Clinical Toxicology (Philadelphia, Pa.), vol. 54, no 7, , p. 563–567 (ISSN1556-9519, PMID27227375, DOI10.3109/15563650.2016.1166508, lire en ligne, consulté le )
issn.org
portal.issn.org
Trista Haupt Wright et Chad Harris, « Twenty-One Cases Involving Alpha-Pyrrolidinovalerophenone (α-PVP) », Journal of Analytical Toxicology, vol. 40, no 5, , p. 396–402 (ISSN1945-2403, PMID27185821, DOI10.1093/jat/bkw029, lire en ligne, consulté le )
Christoph Sauer, Frank T. Peters, Claudia Haas et Markus R. Meyer, « New designer drug alpha-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques », Journal of Mass Spectrometry: JMS, vol. 44, no 6, , p. 952–964 (ISSN1096-9888, PMID19241365, DOI10.1002/jms.1571, lire en ligne, consulté le )
Douglas A. Smith, S. Stevens Negus, Justin L. Poklis et Bruce E. Blough, « Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys », Addiction Biology, vol. 22, no 5, , p. 1169–1178 (ISSN1369-1600, PMID27060605, DOI10.1111/adb.12399, lire en ligne, consulté le )
Asuka Kaizaki, Sachiko Tanaka et Satoshi Numazawa, « New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron », The Journal of Toxicological Sciences, vol. 39, no 1, , p. 1–6 (ISSN1880-3989, PMID24418703, lire en ligne, consulté le )
Kyoko Hataoka, Asuka Kaizaki-Mitsumoto et Satoshi Numazawa, « Alpha-PVP induces the rewarding effect via activating dopaminergic neuron », The Journal of Toxicological Sciences, vol. 42, no 5, , p. 539–543 (ISSN1880-3989, PMID28904288, DOI10.2131/jts.42.539, lire en ligne, consulté le )
Julie A. Marusich, Kateland R. Antonazzo, Jenny L. Wiley et Bruce E. Blough, « Pharmacology of novel synthetic stimulants structurally related to the bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV) », Neuropharmacology, vol. 87, , p. 206–213 (ISSN1873-7064, PMID24594476, PMCIDPMC4152390, DOI10.1016/j.neuropharm.2014.02.016, lire en ligne, consulté le )
Rimako Umebachi, Hiromichi Aoki, Mariko Sugita et Takayuki Taira, « Clinical characteristics of α-pyrrolidinovalerophenone (α-PVP) poisoning », Clinical Toxicology (Philadelphia, Pa.), vol. 54, no 7, , p. 563–567 (ISSN1556-9519, PMID27227375, DOI10.3109/15563650.2016.1166508, lire en ligne, consulté le )
nih.gov
ncbi.nlm.nih.gov
Trista Haupt Wright et Chad Harris, « Twenty-One Cases Involving Alpha-Pyrrolidinovalerophenone (α-PVP) », Journal of Analytical Toxicology, vol. 40, no 5, , p. 396–402 (ISSN1945-2403, PMID27185821, DOI10.1093/jat/bkw029, lire en ligne, consulté le )
Christoph Sauer, Frank T. Peters, Claudia Haas et Markus R. Meyer, « New designer drug alpha-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques », Journal of Mass Spectrometry: JMS, vol. 44, no 6, , p. 952–964 (ISSN1096-9888, PMID19241365, DOI10.1002/jms.1571, lire en ligne, consulté le )
Douglas A. Smith, S. Stevens Negus, Justin L. Poklis et Bruce E. Blough, « Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys », Addiction Biology, vol. 22, no 5, , p. 1169–1178 (ISSN1369-1600, PMID27060605, DOI10.1111/adb.12399, lire en ligne, consulté le )
Asuka Kaizaki, Sachiko Tanaka et Satoshi Numazawa, « New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron », The Journal of Toxicological Sciences, vol. 39, no 1, , p. 1–6 (ISSN1880-3989, PMID24418703, lire en ligne, consulté le )
(en) Meltzer PC, Butler D, Deschamps JR et Madras BK, « 1-(4-Methylphenyl)-2-pyrrolidin-1-ylpentan-1-one (pyrovalerone ) analogs: a promising class of monoamine uptake inhibitors », J. Med. Chem., (PMID16480278, DOI10.1021/jm050797a, lire en ligne)
Kyoko Hataoka, Asuka Kaizaki-Mitsumoto et Satoshi Numazawa, « Alpha-PVP induces the rewarding effect via activating dopaminergic neuron », The Journal of Toxicological Sciences, vol. 42, no 5, , p. 539–543 (ISSN1880-3989, PMID28904288, DOI10.2131/jts.42.539, lire en ligne, consulté le )
Julie A. Marusich, Kateland R. Antonazzo, Jenny L. Wiley et Bruce E. Blough, « Pharmacology of novel synthetic stimulants structurally related to the bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV) », Neuropharmacology, vol. 87, , p. 206–213 (ISSN1873-7064, PMID24594476, PMCIDPMC4152390, DOI10.1016/j.neuropharm.2014.02.016, lire en ligne, consulté le )
Rimako Umebachi, Hiromichi Aoki, Mariko Sugita et Takayuki Taira, « Clinical characteristics of α-pyrrolidinovalerophenone (α-PVP) poisoning », Clinical Toxicology (Philadelphia, Pa.), vol. 54, no 7, , p. 563–567 (ISSN1556-9519, PMID27227375, DOI10.3109/15563650.2016.1166508, lire en ligne, consulté le )
(en) WHO, « 1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-PVP) », Bulletin de l'OMS - Comité d'expertise sur l'abus des drogues, 16-20 novembre 2015, p. 11 (lire en ligne)